• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美托洛尔在大鼠体内外的代谢

Metabolism of metoprolol in the rat in vitro and in vivo.

作者信息

Arfwidsson A, Borg K O, Hoffmann K J, Skånberg I

出版信息

Xenobiotica. 1976 Nov;6(11):691-711. doi: 10.3109/00498257609151681.

DOI:10.3109/00498257609151681
PMID:997586
Abstract
  1. Metoprolol was metabolized in rat liver microsomes in vitro by O-demethylation with subsequent oxidation and by aliphatic hydroxylation of the methoxy-ethyl substituent and by oxidative deamination of the propanolisopropylamine side-chain. The same routes of metabolism in the rat in vivo were revealed from urinary metabolites. Eight metabolites were identified by g.l.c.-mass spectrometry by comparison with synthetized reference compounds. 2. Metoprolol binds to cytochrome-P-450 eliciting a type I difference spectrum with KS = 23 +/- 2-0 muM. The apparent Michaelis-Menten constant Km = 39 +/- 4-0 muM and Vmax = 1-28 +/- 0-22 nmol/mg protein X min were not significantly affected by pre-treatment of the rats with metoprolol or phenobarbital. Metoprolol pre-treatment had no effect on the cytochrome-P-450 level in the microsomes nor on the rate of metabolism of four standard substrates. Phenobarbital increased the cytochrome P-450 as expected. 3. Four metabolites representing the three main routes of metabolism were quantitatively determined after metabolism with rat liver microsomes and compared with the urinary levels of the same compounds. The same major metabolites were found in vitro and in vivo. The total amount of metabolites was not influenced by pre-treatment with metoprolol or phenobarbital. The relative amounts of the three main metabolites were slightly affected by pre-treatment.
摘要
  1. 美托洛尔在大鼠肝微粒体中体外代谢通过O-去甲基化随后氧化、甲氧基乙基取代基的脂肪族羟基化以及丙醇异丙胺侧链的氧化脱氨作用进行。从尿代谢物中揭示了大鼠体内相同的代谢途径。通过与合成参考化合物比较,用气相色谱-质谱法鉴定了8种代谢物。2. 美托洛尔与细胞色素P-450结合,产生KS = 23±2.0 μM的I型差异光谱。表观米氏常数Km = 39±4.0 μM,Vmax = 1.28±0.22 nmol/mg蛋白质×分钟,用美托洛尔或苯巴比妥预处理大鼠对其无显著影响。美托洛尔预处理对微粒体中细胞色素P-450水平以及四种标准底物的代谢速率均无影响。苯巴比妥如预期那样增加了细胞色素P-450。3. 在用大鼠肝微粒体代谢后,对代表三种主要代谢途径的四种代谢物进行了定量测定,并与相同化合物的尿水平进行了比较。在体外和体内发现了相同的主要代谢物。代谢物的总量不受美托洛尔或苯巴比妥预处理的影响。三种主要代谢物的相对量受预处理的轻微影响。

相似文献

1
Metabolism of metoprolol in the rat in vitro and in vivo.美托洛尔在大鼠体内外的代谢
Xenobiotica. 1976 Nov;6(11):691-711. doi: 10.3109/00498257609151681.
2
Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.新型抗微管蛋白剂6-甲氧基-3-(3',4',5'-三甲氧基-苯甲酰基)-1H-吲哚(BPR0L075)在小鼠、大鼠、犬和人肝微粒体中的生物转化。
Drug Metab Dispos. 2007 Jul;35(7):1042-9. doi: 10.1124/dmd.106.014597. Epub 2007 Apr 2.
3
Metabolism of roxithromycin in phenobarbital-treated rat liver microsomes.罗红霉素在苯巴比妥处理的大鼠肝微粒体中的代谢。
Acta Pharmacol Sin. 2002 May;23(5):455-60.
4
Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes.维拉帕米对人肝微粒体中美托洛尔对映体选择性氧化代谢的抑制作用。
Drug Metab Dispos. 1993 Mar-Apr;21(2):309-17.
5
Microsomal oxidation of N,N-diethylformamide and its effect on P450-dependent monooxygenases in rat liver.N,N-二乙基甲酰胺的微粒体氧化及其对大鼠肝脏中细胞色素P450依赖的单加氧酶的影响。
Chem Res Toxicol. 1996 Jul-Aug;9(5):882-90. doi: 10.1021/tx950201u.
6
In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo.抗焦虑药物丁螺环酮的体外代谢作为其体内代谢的预测指标
Xenobiotica. 1990 Aug;20(8):779-86. doi: 10.3109/00498259009046892.
7
Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6.由含有经cDNA表达的人P4502D6的微粒体催化的美托洛尔和布呋洛尔的区域选择性和立体选择性氧化。
Drug Metab Dispos. 1995 Apr;23(4):513-7.
8
Oxidative metabolism of monensin in rat liver microsomes and interactions with tiamulin and other chemotherapeutic agents: evidence for the involvement of cytochrome P-450 3A subfamily.莫能菌素在大鼠肝微粒体中的氧化代谢及其与泰妙菌素和其他化疗药物的相互作用:细胞色素P-450 3A亚家族参与的证据
Drug Metab Dispos. 1999 Sep;27(9):1039-44.
9
Bioactivation of 8-methoxypsoralen and irreversible inactivation of cytochrome P-450 in mouse liver microsomes: modification by monoclonal antibodies, inhibition of drug metabolism and distribution of covalent adducts.8-甲氧基补骨脂素在小鼠肝脏微粒体中的生物活化及细胞色素P-450的不可逆失活:单克隆抗体的修饰、药物代谢抑制及共价加合物的分布
J Pharmacol Exp Ther. 1990 Aug;254(2):720-31.
10
The effect of certain vitamin deficiencies on hepatic drug metabolism.某些维生素缺乏对肝脏药物代谢的影响。
Fed Proc. 1976 Nov;35(13):2464-9.

引用本文的文献

1
Soft drugs. XX. Design, synthesis, and evaluation of ultra-short acting beta-blockers.软性毒品。XX。超短效β受体阻滞剂的设计、合成与评价。
Pharm Res. 1995 Mar;12(3):329-36. doi: 10.1023/a:1016283930696.
2
The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.肾功能受损对美托洛尔代谢物血浆浓度及尿排泄的影响。
Clin Pharmacokinet. 1980 Mar-Apr;5(2):181-91. doi: 10.2165/00003088-198005020-00005.
3
Effect of rifampicin on metoprolol and antipyrine kinetics.利福平对美托洛尔和安替比林药代动力学的影响。
Br J Clin Pharmacol. 1982 Mar;13(3):387-91. doi: 10.1111/j.1365-2125.1982.tb01390.x.
4
Increased oral clearance of metoprolol in pregnancy.
Eur J Clin Pharmacol. 1983;24(2):217-20. doi: 10.1007/BF00613820.
5
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.β-肾上腺素能受体拮抗剂的多态性氧化。临床药代动力学考量。
Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001.
6
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.美托洛尔代谢与异喹胍氧化多态性——群体与家系研究
Br J Clin Pharmacol. 1985 Dec;20(6):555-66. doi: 10.1111/j.1365-2125.1985.tb05112.x.
7
Metoprolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.美托洛尔:其药理学特性及在高血压和心绞痛治疗中的疗效综述。
Drugs. 1977 Nov;14(5):321-48. doi: 10.2165/00003495-197714050-00001.
8
Species differences in the metabolism of pamatolol, a cardioselective beta--adrenoceptor antagonist.帕马洛尔(一种心脏选择性β-肾上腺素能受体拮抗剂)代谢的种属差异。
Eur J Drug Metab Pharmacokinet. 1979;4(3):163-73. doi: 10.1007/BF03189420.